C12Y 304/00
Hydrolases acting on peptide bonds, i.e. peptidases
Official title: Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
C12Y304/00 (Hydrolases acting on peptide bonds, i.e. peptidases) appears on 4,541 US grants and 7,396 published applications in this corpus.
Search patents in C12Y- Granted patents
- 4,541
- Published applications
- 7,396
- Assignees
- 2,551
- Inventors
- 12,353
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 7 | 0 |
| 1977 | 7 | 0 |
| 1978 | 5 | 0 |
| 1979 | 6 | 0 |
| 1980 | 4 | 0 |
| 1981 | 15 | 0 |
| 1982 | 13 | 0 |
| 1983 | 7 | 0 |
| 1984 | 10 | 0 |
| 1985 | 15 | 0 |
| 1986 | 9 | 0 |
| 1987 | 16 | 0 |
| 1988 | 13 | 0 |
| 1989 | 17 | 0 |
| 1990 | 36 | 0 |
| 1991 | 40 | 0 |
| 1992 | 52 | 0 |
| 1993 | 49 | 0 |
| 1994 | 43 | 0 |
| 1995 | 43 | 0 |
| 1996 | 56 | 0 |
| 1997 | 74 | 0 |
| 1998 | 100 | 0 |
| 1999 | 91 | 0 |
| 2000 | 67 | 0 |
| 2001 | 60 | 13 |
| 2002 | 47 | 82 |
| 2003 | 63 | 142 |
| 2004 | 44 | 132 |
| 2005 | 47 | 104 |
| 2006 | 45 | 125 |
| 2007 | 49 | 107 |
| 2008 | 62 | 142 |
| 2009 | 43 | 146 |
| 2010 | 70 | 163 |
| 2011 | 74 | 195 |
| 2012 | 100 | 201 |
| 2013 | 98 | 200 |
| 2014 | 132 | 277 |
| 2015 | 183 | 399 |
| 2016 | 199 | 478 |
| 2017 | 227 | 497 |
| 2018 | 266 | 423 |
| 2019 | 298 | 486 |
| 2020 | 293 | 439 |
| 2021 | 299 | 451 |
| 2022 | 244 | 441 |
| 2023 | 214 | 507 |
| 2024 | 221 | 488 |
| 2025 | 216 | 406 |
| 2026 | 152 | 352 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 304/21Serine endopeptidases2,758
- C12Y 304/24Metalloendopeptidases1,032
- C12Y 304/22Cysteine endopeptidases388
- C12Y 304/23Aspartic endopeptidases183
- C12Y 304/17Metallocarboxypeptidases113
- C12Y 304/14Dipeptidyl-peptidases and tripeptidyl-peptidases84
- C12Y 304/11Aminopeptidases61
- C12Y 304/19Omega peptidases56
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Protease composition6 Oct 2026US 12,751,997 B2Anatara Lifesciences Limited
- CAS12B enzymes and systems6 Oct 2026US 12,753,406 B2Massachusetts Institute of Technology
- Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement6 Oct 2026US 12,753,411 B2The Brigham and Women S Hospital, Inc.
- Cleaning compositions comprising dispersins VI29 Sep 2026US 12,747,416 B2Henkel AG & Co. KGaA
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Human factor vii deletion constructs for treating cancer8 Oct 2026US 2026/0306592 A1The Cleveland Clinic Foundation
- Stabilized liquid and lyophilized adamts13 formulations8 Oct 2026US 2026/0306593 A1Takeda Pharmaceutical Company Limited
Most cited
By later US patents
- Plasminogen activator derivatives616US 4,640,835 ANippon Chemiphar Co., Ltd. · 1987
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Method for dominant selection in eucaryotic cells277US 5,122,464 ACelltech Limited, a British Company · 1992